Insulet to Present at the Jefferies Global Healthcare Conference

Rhea-AI Summary

Insulet (NASDAQ: PODD) announced that its management will present at the Jefferies Global Healthcare Conference in New York City on June 6, 2024, at 9:00 a.m. ET. The presentation will be accessible via a live audio webcast on the company's investor relations site, with a replay available post-event.

Insulet is renowned for its Omnipod® product platform, a tubeless insulin pump technology aimed at simplifying life for people with diabetes. The Omnipod Insulin Management System offers up to three days of non-stop insulin delivery without needle handling. Their latest innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor and can be controlled via smartphone or the Omnipod 5 Controller. Insulet is also exploring the use of its Omnipod technology for non-insulin subcutaneous drug delivery.

Positive

• Management presentation at a prominent conference like Jefferies Global Healthcare Conference could attract investor interest and improve stock visibility.
• The Omnipod 5 Automated Insulin Delivery System is an advanced product that integrates with a continuous glucose monitor, providing a competitive edge.
• Expanding the use of Omnipod technology for non-insulin subcutaneous drug delivery demonstrates growth potential in multiple therapeutic areas.

Negative

• No immediate financial data or clinical results presented in the PR, making it difficult to assess near-term stock impact.
• The announcement lacks concrete business developments or partnerships, which might be seen as a missed opportunity for significant positive news.

ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod^® brand of products, today announced that management will present at the Jefferies Global Healthcare Conference in New York City on Thursday, June 6, 2024 at 9:00 a.m. (Eastern Time).

To listen to the live audio webcast of the presentation, please visit investors.insulet.com/events. A replay of the webcast will also be available following the event.

About Insulet Corporation:

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, is a tubeless automated insulin delivery system, integrated with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be fully controlled by a compatible personal smartphone or the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, please visit: insulet.com and omnipod.com.

©2024 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation. All rights reserved.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240527181999/en/

Investor Relations:

Deborah R. Gordon

Vice President, Investor Relations

(978) 600-7717

dgordon@insulet.com

Media:

Angela Geryak Wiczek

Senior Director, Corporate Communications

(978) 932-0611

awiczek@insulet.com

Source: Insulet Corporation

FAQ

When will Insulet present at the Jefferies Global Healthcare Conference?

Insulet will present at the Jefferies Global Healthcare Conference on June 6, 2024, at 9:00 a.m. ET.

Where can I listen to Insulet's presentation at the Jefferies Global Healthcare Conference?

You can listen to the live audio webcast of Insulet's presentation on their investor relations website. A replay will also be available after the event.

What is Insulet's flagship product?

Insulet's flagship product is the Omnipod 5 Automated Insulin Delivery System, a tubeless insulin pump that integrates with a continuous glucose monitor.

What is the stock symbol for Insulet ?

The stock symbol for Insulet is NASDAQ: PODD.

What is unique about the Omnipod Insulin Management System?

The Omnipod Insulin Management System offers a tubeless, wearable design that provides up to three days of non-stop insulin delivery without the need to handle needles.

Is Insulet expanding the use of its Omnipod technology?

Yes, Insulet is tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas.